Fig. 6
5-FU enhances the therapeutic outcome of the PEPDG278D-centered combination treatment. a-c Mice bearing subcutaneous tumors were treated with EP daily (HCT116 tumors: days 3–20; HT29 tumors: days 3–17; PDX14650: days 4–23), or EP daily plus aderbasib daily (HCT116 tumors: days 4–20; HT29 tumors: days 4–17; PDX14650: days 6–23) plus PEPDG278D thrice weekly (HCT116 tumors: days 5–19; HT29 tumors: days 5–17; PDX14650: days 7–23) plus 5-FU every 3–4 days (HCT116 tumors: days 6–20; HT29 tumors: days 6–17; PDX14650: days 8–23). EP, PEPDG278D, and 5-FU were administered to mice by ip at 0.5, 4 and 35 mg/kg per dose, respectively. Aderbasib was administered to mice by gavage at 60 mg/kg per dose. Group average tumor volumes were 59–64 mm3 (HCT116 tumors), 153–185 mm3 (HT29 tumors), and 193–226 mm3 (PDX14650) at the beginning of treatment. Each value is mean ± SEM (n = 13–16). ****P < 0.0001 by two-tailed unpaired t test. d Western blotting of tumor homogenates (2 tumors per group). Tumors were harvested 24 or 48 h after final PEPDG278D treatment. See Fig. 1 and Fig. 2 legends for protein phosphorylation sites